


PHARMACEUTICAL 2020

Blueprint Medicines Corp Rank 190 of 362







PHARMACEUTICAL 2020

Blueprint Medicines Corp Rank 190 of 362



The relative strengths and weaknesses of Blueprint Medicines Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Blueprint Medicines Corp compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 41% points. The greatest weakness of Blueprint Medicines Corp is the variable Research and Development, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is -190%, being 112% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	516,786
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	106,482
Liabilities, Non-Current	136,853
Other Assets	152,547
Other Compr. Net Income	-2,354
Other Expenses	0
Other Liabilities	0
Other Net Income	13,632
Property and Equipment	38,361
Research and Development	331,450
Revenues	66,512
Selling, General and Administrative Expense	96,388

Output Variable	Value in 1000 USD
Assets	707,694
Liabilities	243,335
Expenses	427,838
Stockholders Equity	464,359
Net Income	-347,694
Comprehensive Net Income	-348,871
Economic Capital Ratio	-190%